Drugs / tRF-ASO-Exo-PAE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07382453 | Feb 2026 → Dec 2028 expected | keratopathy | Affiliated Hospital of Nantong University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tRF-ASO-Exo-PAE | “Group 3 (tRF-ASO-Exo-PAE) receives 10 μg/drop of tRF-ASO-engineered MSC-Exos delivered via PAE hydrogel.” NCT07382453 ↗ |
| Route | Topical | “topical application of PAE hydrogel loaded with tRF-targeting ASO-engineered mesenchymal stem cell-derived exosomes” NCT07382453 ↗ |